<\/p>\n
Access to quality treatment can mean the difference between life and death for the more than 24,000 people in Colorado expected to be diagnosed with cancer this year.<\/p>\n
New and experimental drugs are extending the lives of people with the deadliest forms of cancer. At the University of Colorado Cancer Center in Aurora, Dr. Ross Camidge leads clinical trials for lung cancer, which kills more people each year than breast cancer, colon cancer and pancreatic cancer combined.<\/p>\n
Camidge calls them \u201cniche-busters\u201d \u2013 targeted therapies that dig deep into the profiles of each individual cancer. Researchers have discovered that just as individual patients have different genetic make-ups, so do their tumors.<\/p>\n
The revolution in the past decade has been in diagnosing and treating cancer at the molecular level, says Camidge.<\/p>\n
\u201cIt\u2019s not one miracle drug,\u201d says Camidge. \u201cIt\u2019s lots of different miracles for lots of different cancers.\u201d<\/p>\n
His patient Polly Rogers is a former soap opera star \u2013 she was \u201cnaughty girl\u201d Kate Lodge on \u201cThe Secret Storm\u201d \u2013 and a retired professor of public speaking at Arapahoe Community College who lives in Highlands Ranch. She is enrolled in a clinical trial using a combination of dabrafenib and trametinib. British pharmaceutical company GlaxoSmithKline won licenses for the two drugs in 2013 to treat melanoma for patients who exhibited a mutation in a gene called BRAF.<\/p>\n
The mutation is common in melanoma but rare among patients with lung cancer. Rogers is one of only around 4,000 people nationwide who have the mutation. Fewer than three dozen people around the country are enrolled in a trial to see if the drugs can also slow tumor growth in lung cancer as they do for melanoma.<\/p>\n
The regimen has worked for Rogers.<\/p>\n
\u201cThe cancer has melted away,\u201d Camidge told Rogers, during a recent visit. He showed her a line chart that plummeted toward zero. He asked her about side effects. She had missed a dose because of an intolerably high fever, and she had a rash.<\/p>\n
Rogers said she felt \u201csomewhat of a shock\u201d when she first received her diagnosis in January 2013. She and her husband had been avid travelers, saving their money for trips to Australia, New Zealand, Jordan, Iceland, France. Scotland was her favorite; she turns actress when she slips into a Scottish accent. Since the diagnosis, they\u2019ve traveled closer to home, opting for jaunts to the Columbia River, New Mexico, and Florida to visit the grandkids.<\/p>\n
\u201cI was told when I met with a doctor first that I had less than a year to live,\u201d says Rogers, in a voice that is raspy but clear. \u201cHere I am more than two years later, being frisky. So not bad.\u201d<\/p>\n
The University of Colorado Hospital is among the top-ranked cancer treatment centers in the nation, according to U.S. News and World Report. Outcomes for its cancer patients routinely top state and national rates. The Cancer Center is one of 68 institutions given a special designation by the National Cancer Institute to conduct cancer research, the only such facility in the state.<\/p>\n
Clinical trials provide a chance to try a potentially life-saving treatment with little or no financial cost. They also give patients access to drugs that are not yet available on the market. But being the first to try a drug can be costly in its own way.<\/p>\n
Michael Moore was a high school basketball coach in Pueblo when he was diagnosed with stage four lung cancer on his 40th birthday. It blindsided him; he worked out with his students, and was never a smoker. Moore jumped on the chance to try a drug targeted to the EGFR gene mutation that he exhibits.<\/p>\n
\u201cIt feels like walking into a dark room,\u201d Moore says of the clinical trial. \u201cBut anything that\u2019s going to prolong my life, I\u2019m going to try.\u201d<\/p>\n
It controlled his cancer. But it also caused brutal side effects, unknown before he exhibited them. Moore went blind.<\/p>\n
As Camidge explains it, a drug-induced diabetes brought on cataracts. They developed over just two days, says Moore. He lived in darkness for three weeks until surgery restored his eyesight.<\/p>\n
Other promising treatments, says Camidge, spark the immune system to attack cancer. In about one in five people, cancer stimulates the immune system. But cancer expresses a molecule that allows it to hide from immune attack. New drugs block that communication, leaving the cancer exposed.<\/p>\n
\u201cMy job is to pick the winners (among the clinical trials) in advance,\u201d says Camidge. \u201cWe\u2019ve been pretty good at that.\u201d<\/p>\n
The odds of surviving stage four lung cancer are disheartening. Nationwide, fewer than three percent of those diagnosed will live five years. At the University of Colorado Hospital, the odds are twice as good, but still just more than five percent.<\/p>\n
There is still no cure. Cancers eventually adapt to the drugs. Some adapt quickly, and some adapt slowly.<\/p>\n
But the numbers don\u2019t tell the full story. They don\u2019t tell the story of what people decide to do with their time when, as Camidge puts it, \u201cthey\u2019re staring down the barrel of a gun.\u201d<\/p>\n